Key facts
- Spirair’s last known valuation is $46.0M (Mar 2026).
- It has raised $34.7M across 1 recorded rounds; the latest was Early Stage VC ($24.7M) in Jul 2025.
- Notable investors include Sonder Capital Management, 1809 Capital, Cadence Healthcare Ventures, View Ventures.
- Spirair has filed 2 Form Ds with the SEC since 2025, most recently Mar 2026 ($24.7M sold to 55 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Spirair
Funding rounds
1 roundsAbout Spirair
Developer of minimally invasive medical devices designed to treat nasal septal deviation. The company's device transforms the nasal obstruction treatment procedure from surgery to an in-office procedure, providing doctors with strong outcomes and a better patient experience.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2020
- Employees
- 24
- Website
- spirair.com/
- Ownership
- Privately Held (backing)
Spirair doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spirair shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spirair in its N-PORT filings yet. We sweep new filings monthly.